1 week ago
AstraZeneca (AZN) Stock Climbs on Promising Enhertu Cancer Trial Data
AstraZeneca (AZN) stock rises after successful Enhertu Phase 3 trial demonstrates improved outcomes in HER2-mutant lung cancer first-line treatment.
The post AstraZeneca (AZN) Stock Climbs on Promising Enhertu Cancer Trial Data appeared first on Blockonomi.
Source: Blockonomi →Related News
- 1 hour ago
Bitcoin (BTC) Surges Past $80K as Nvidia Earnings Exceed Expectations
- 11 hours ago
The Trade Desk, Inc. (TTD) Stock: New Zuma Platform Brings Smarter AI, Simpler M...
- 12 hours ago
Laser Photonics Corporation (LASE) Stock: SOCOM Engagement Puts Counter-Drone Sy...
- 14 hours ago
Amazon (AMZN) Stock: Expands Nvidia Partnership as AI Demand Grows
- 15 hours ago
Marvell Technology (MRVL) Q2 Earnings Preview: Should Investors Buy Before Thurs...